Stereotactic Ablative Radiotherapy for Oligometastatic Hepatocellular Carcinoma

Inclusion Criteria

• •i. 19 years or older
• •ii. Patients who signed the informed consent form
• •iii. The clinical trial protocol can be complied with at the discretion of the investigator
• •iv. Performance status (based on ECOG) less than 2 (0, 1)
• •v. Patients with life expectancy greater than 3 months
• •vi. Condition in which primary cancer is controlled
• •Definition: A condition that has not progressed at the time of review of clinical trials after curative treatment of primary cancer 3 months ago
• •vii. Number of metastatic lesions up to 5
• •viii. 3 or less metastatic lesions in one metastatic organ
• •ix. Those who are undergoing targeted therapy or chemotherapy can also be included (during radiation therapy, drug treatment is stopped)